title: Choroidal neovascularization of optic disk melanocytoma treated with bevacizumab.
abstract: OBJECTIVE
  To report a case of choroidal neovascularization (CNV) associated with optic disk melanocytoma successfully treated with bevacizumab.
  
  
  METHODS
  A 63-year-old man complained of visual impairment in his left eye. His visual acuity was 0.9 OS. Fundus examination showed optic disk melanocytoma associated with serous retinal detachment and mild hemorrhage. Fluorescein and indocyanine green angiography revealed CNV adjacent to the optic disc. Intravitreous bevacizumab (IVB) was performed 3 times.
  
  
  RESULTS
  Choroidal neovascularization and serous retinal detachment disappeared at 5 months after IVB. Visual acuity recovered to 1.5 OS and has been stable for 1 year follow-up. No adverse events were found related to IVB.
  
  
  CONCLUSIONS
  Intravitreous bevacizumab can be a beneficial treatment for CNV associated with optic disc melanocytoma.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Kagoshima University Graduate School of Medicine and Dental Sciences, Kagoshima, Japan.
authors.forename: Taro
authors.initials: T
authors.lastname: Kamisasanuk
authors.forename: Eisuke
authors.initials: E
authors.lastname: Uchino
authors.forename: Taiji
authors.initials: T
authors.lastname: Sakamoto
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D004396:Coloring Agents; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009508:Nevus, Pigmented / Q000473:pathology*; D009898:Optic Disk / Q000098:blood supply / Q000473:pathology*; D019574:Optic Nerve Neoplasms / Q000473:pathology*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014794:Visual Fields / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007208:Indocyanine Green